Want to see TSE:AYUR full AI Analyst Report?
AYUR Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)59.98K
Market Cap
C$1.95M
Enterprise ValueC$1.52M
Total Cash (Recent Filing)C$1.09M
Total Debt (Recent Filing)C$667.58K
Price to Earnings (P/E)―
Beta-0.85
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding194,703,860
10 Day Avg. Volume17,939
30 Day Avg. Volume59,984
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-1.65
Price to Sales (P/S)0.16
P/FCF Ratio2.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained TTM revenue growth of +55.3% indicates expanding product adoption and market penetration. For 2–6 months outlook this growth underpins scale economies, supports negotiating power with retailers/partners, and creates a clearer pathway to operational leverage if cost control improves.
Proprietary Extraction & Product BreadthProprietary extraction tech plus a diversified product portfolio (medical and recreational oils, capsules, edibles) is a durable competitive advantage. It enables higher-quality inputs, B2B sales, private-label opportunities, and differentiation that supports long-term distribution agreements and margin resilience.
Solid Gross Margin BaseA 36.7% gross profit margin provides a healthy product-level buffer. If operating expenses are managed, this margin foundation can translate into improved EBIT margins over months, allowing the company to reinvest in R&D and distribution while withstanding commodity cost swings common in cannabis manufacturing.
Bears Say
Balance-sheet Solvency RiskNegative equity and extreme leverage signal structural solvency risk. Over 2–6 months this constrains strategic flexibility, increases refinancing or covenant risks, and raises the likelihood of dilutive capital raises or asset sales to shore up liquidity, limiting long-term stability.
Weak Cash GenerationA 72.4% decline in free cash flow and negative operating cash flow relative to net income indicate poor internal cash conversion. This weak cash generation pressures working capital, restricts capex and marketing investments, and forces reliance on external funding, affecting durable growth plans.
Persistent UnprofitabilityNegative EBIT and a -12.5% net margin show ongoing inability to translate sales into profit. Absent structural cost reductions or pricing power improvements, sustained losses will erode equity, impede reinvestment, and make achieving durable profitability within months challenging.
Ayurcann Holdings Corp. News
AYUR FAQ
What was Ayurcann Holdings Corp.’s price range in the past 12 months?
Ayurcann Holdings Corp. lowest stock price was <C$0.01 and its highest was C$0.04 in the past 12 months.
What is Ayurcann Holdings Corp.’s market cap?
Ayurcann Holdings Corp.’s market cap is C$1.95M.
When is Ayurcann Holdings Corp.’s upcoming earnings report date?
Ayurcann Holdings Corp.’s upcoming earnings report date is Nov 02, 2026 which is in 123 days.
How were Ayurcann Holdings Corp.’s earnings last quarter?
Currently, no data Available
Is Ayurcann Holdings Corp. overvalued?
According to Wall Street analysts Ayurcann Holdings Corp.’s price is currently Overvalued.
Does Ayurcann Holdings Corp. pay dividends?
Ayurcann Holdings Corp. does not currently pay dividends.
What is Ayurcann Holdings Corp.’s EPS estimate?
Ayurcann Holdings Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ayurcann Holdings Corp. have?
Ayurcann Holdings Corp. has 194,703,860 shares outstanding.
What happened to Ayurcann Holdings Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ayurcann Holdings Corp.?
Currently, no hedge funds are holding shares in TSE:AYUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ayurcann Holdings Corp.
Ayurcann Holdings Corp. provides comprehensive post-harvest outsourcing solutions for licensed cannabis producers throughout Canada. Its end-to-end services encompass various stages, including raw material extraction and refinement, bulk distillate oil sales, product formulation, and white-label manufacturing. The company further supports clients with fulfillment, distribution, custom packaging development, and inventory control. In addition to these business-to-business services, Ayurcann produces and markets its own line of medicinal cannabis products, such as tinctures, vapes, and topicals. It also manages the Ayurcann marketplace, an e-commerce platform dedicated to medical cannabis consumers. The company was founded in 2018 and is based in Pickering, Canada.